The combined use of antiplatelet drugs acting through different mechanisms is important in antithrombotic treatment of patients with cardiovascular disease. The improvement of our knowledge on the ...

New P2Y 12 inhibitors, such as prasugrel and ticagrelor, have favorable pharmacodynamics and clinical efficacy over clopidogrel and offer an alternative antiplatelet treatment strategy in specific ...

A primary benefit of abbreviated antiplatelet therapy is a significant ... Careful risk assessment and tailored treatment strategies are crucial. “[Diabetes mellitus] remains an independent ...

The risk for recurrent cardiovascular events is high among patients with r-axSpA and a history of these events, though TNF inhibitor therapy may offer protective benefits.

In some cases, aspirin is combined with another antiplatelet medication in a treatment known as dual antiplatelet therapy ...

While aspirin is traditionally the standard antiplatelet agent ... No significant interaction was observed between treatment effects and the presence of HBR or PCI complexity, indicating that ...